Researchers in South Korea have combined the genes of more than 1.1 million people with a cell-level look at diseased skin to pin down why psoriasis flares in the first place.
Their screen narrowed the field to 50 genes as promising targets for future drugs, a shortlist that could shape the next wave of treatments for a condition that affects about 8 million people in the United States.
The work, published in Nature Communications, was led by Professor Hong-Hee Won at the Samsung Advanced Institute for Health Sciences and Technology at Sungkyunkwan University. It is one of the largest genetic analyses of psoriasis to date.
What the study actually did
The team ran a meta-analysis of genome-wide association data, a method that scans DNA for tiny differences that show up more often in people with a disease.
Also read: Your pregnancy phone habit could reach the fetal heart, a new review suggests
They identified 125 genetic spots linked to psoriasis onset. Seventeen of those had never been reported before.
They then layered on single-cell transcriptomic analysis, a technique that reads gene activity one cell at a time in skin samples from healthy people and psoriasis patients. That let them see which cell types were driving the disease.
Four cell populations kept showing up. Myeloid cells and T cells, both part of the immune system, were interacting with keratinocytes on the skin's surface and with endothelial cells lining nearby blood vessels.
Together, those cells fueled the runaway inflammation that produces the red, scaly plaques psoriasis is known for.
Also read: New advice: How to reduce discomfort during vaccination
A shortlist of 50 gene targets
By combining the genetic signals with the cell-by-cell activity, the researchers narrowed thousands of possibilities down to 50 candidate genes for future drug development, according to the Sungkyunkwan University announcement.
"This research combines large-scale genomic data with precise cellular transcriptomic analysis to clearly reveal which genetic factors and cell types are involved in psoriasis pathology," Professor Won said in the announcement.
Why this matters for patients
Psoriasis is not just a skin condition. The National Psoriasis Foundation notes that people with psoriasis have higher rates of cardiovascular disease, heart attack, stroke, metabolic syndrome and depression, and about 30 percent go on to develop psoriatic arthritis, a form of inflammatory joint disease.
Existing biologic drugs already work well for many patients by dampening specific immune signals, as summarized in a 2026 review of the IL-23/IL-17 axis in psoriasis.
Also read: This is how long the body can take to catch up on lost sleep
Not everyone responds to these drugs, and they manage the inflammation rather than address its root cause.
A shortlist of validated gene targets gives drugmakers concrete leads for new approaches. There is also room to spot warning signs earlier, as 8 early signs of psoriasis that people often mistake for dry skin show up long before a formal diagnosis.
This paper does not change what is available at the pharmacy today. Turning a gene target into an approved drug typically takes many years of preclinical work and clinical trials.
People with psoriasis symptoms should talk to a dermatologist, who can match treatment to disease severity and other health conditions.
Also read: A bargain eyelid lift abroad may cost you the ability to close your eyes
Also read: A rare infection during pregnancy may triple your child's risk of autism
This article is made and published by Mie Hermansen, who may have used AI in the preparation.